ZURICH (Reuters) - Novartis AG has found new liver safety problems with high doses of its diabetes medicine Galvus, delaying the key drug’s path to market in Europe and raising further questions over its future.
ZURICH (Reuters) - Novartis AG has found new liver safety problems with high doses of its diabetes medicine Galvus, delaying the key drug’s path to market in Europe and raising further questions over its future.
